Novartis Ag ADR (NY: NVS )
98.50 -1.16 (-1.16%) Official Closing Price Updated: 7:00 PM EDT, Jun 7, 2023 Add to My Watchlist
Headline News about Novartis Ag ADR
Looking At Novartis's Recent Unusual Options Activity
June 01, 2023
Immix Biopharma's Subsidiary Says Investigational CAR T Therapy Shows 100% Response Rate In Amyloidosis
May 22, 2023
Immix Biopharma Inc's (NASDAQ: IMMX) subsidiary Nexcella Inc announced updated AL Amyloidosis clinical data from its ongoing Phase 1b/2a NEXICART-1 study of its BCMA-targeted chimeric antigen receptor...
Why Novartis Stock Is Trading Higher Today
April 25, 2023
Amgen Inc (NASDAQ: AMGN) has reportedly sued Novartis AG's (NYSE: NVS) Generic arm Sandoz on proposed versions of its bone-strengthening drugs Prolia and Xgeva containing denosumab, infringing several...
Earnings Preview: Novartis
April 24, 2023
After Q1 Review, Novartis Narrows R&D Pipeline To Prioritize High-Value Transformative Medicines
April 25, 2023
In its Q1 FY23 earnings release, Novartis AG (NYSE: NVS) announced cutting its pipeline by around 10% as CEO Vas Narasimhan's campaign to turn it into a "pure-play" drugmaker goes full steam.
Alzheimer's Disease Largely Remains A Mystery, With A Lack Of Highly Effective Treatments — Could Regulatory T-Cells (Tregs) Be The Answer?
April 13, 2023
In many ways, Alzheimer's disease (AD) remains a mystery. Most common in those over 65, AD is the most common form of dementia, but its exact causes remain unclear, and treatments are unable to halt or...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following